Multiple authors have recently analysed various immunohematologic findings in patients with coronavirus disease 2019 (COVID-19), some of which have shown highly disparate results (Table 1). [1][2][3][4][5][6] For example, Pandey et al. recently published a description of the prevalence of direct antiglobulin test (DAT) positivity in patients admitted to the intensive care unit (ICU), showing that the DAT was positive in 17.3% (50/289) of their cohort. 1 They compared this to a DAT-positivity frequency of 46% (52/113) in a study of hospitalised patients with COVID-19 by Berzuini et al. (which Pandey et al. incorrectly referenced as 26%). 2 At first, these findings appear quite discrepant; how-